446 results on '"Rodriguez, Maria Alma"'
Search Results
2. Ethics in Cancer Care Delivery—Do Not Resuscitate
3. Contributors
4. Improving advance care planning for patients receiving chimeric antigen receptor T-cell therapy with lymphoma and myeloma.
5. Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma
6. Hematologic Cancer Survivorship Management: Lymphoma
7. Models of Survivorship Care
8. Introduction
9. Primary Analysis of a Pilot Study of Prophylactic Anakinra to Mitigate CAR T Cell-Associated Toxicity in Patients with Relapsed or Refractory Large B-Cell Lymphoma
10. CD19 CAR-T Outcomes in Patients with EBV-Positive DLBCL
11. Phase II Study of Pembrolizumab and Fractionated External Beam Radiotherapy in Patients with Relapsed and Refractory Large B-Cell Lymphoma
12. 57 - Ética en la prestación de cuidados oncológicos: órdenes de no reanimar
13. 57 - Ethics in Cancer Care Delivery—Do Not Resuscitate
14. List of Contributors
15. Ethical Issues in Cancer Survivorship
16. Brentuximab vedotin and nivolumab alone and then combined with rituximab, cyclophosphamide, doxorubicin, and prednisone for frontline therapy of patients with primary mediastinal large B-cell lymphoma.
17. Symptom profile of head and neck patients initiating care in a survivorship clinic.
18. Long-term outcomes and circulating tumor DNA analysis from a phase I/II study of lenalidomide and obinutuzumab with CHOP for newly diagnosed diffuse large B-cell lymphoma.
19. Real-world analysis of safety and efficacy of CAR T-cell therapy in patients with lymphoma with decreased renal function.
20. Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma
21. The Absolute Monocyte and Lymphocyte Prognostic Index for Patients With Diffuse Large B-Cell Lymphoma Who Receive R-CHOP
22. Vaccinations for Patients With Cancer and Cancer Survivors
23. Smart Stop: A Phase II Study of Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Chemotherapy in Patients with Newly Diagnosed DLBCL
24. Ten Year Follow up of the MD Anderson Cancer Center Phase 2 Study of Rituximab in Combination with Lenalidomide (R2) for Patients with Low Tumor Burden Follicular Lymphoma
25. Outcome of Patients with T- Cell Histiocyte Rich B Cell Lymphoma: Single Institution Series
26. Phase II Trial of Response Adapted Ultra Low Dose (ULD) Orbital Radiation Therapy for Indolent B Cell Lymphoma
27. Pacific: A Phase II Study of Brentuximab Vedotin and Nivolumab Alone and then Combined with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Patients with Untreated Primary Mediastinal Large B-Cell Lymphoma
28. A Risk Score Incorporating Low Pass Whole Genome Sequencing of Cell Free DNA from Patients Receiving CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma
29. Implementation of ePROs in the care of long-term cancer survivors.
30. Patterns of virtual care among long-term cancer survivors.
31. Innovating the Personalization of Stratified Survivorship Care Pathways: Using a Cancer Data Ecosystem to Improve Care Access, Outcomes, Efficiency, and Costs
32. Radiation for diffuse large B-cell lymphoma in the rituximab era: Analysis of the National Comprehensive Cancer Network lymphoma outcomes project
33. Introduction
34. Models of Survivorship Care
35. Hematologic Cancer Survivorship Management: Lymphoma
36. Outcomes in Patients with Relapsed Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Treated with CAR-T Cell Therapies or Salvage Chemotherapy - a Single-Institution Experience
37. Nivolumab and Ibrutinib for Treatment of Patients with Refractory or Relapsed Central Nervous System Lymphoma
38. Addition of Acalabrutinib to Lenalidomide and Rituximab Induces High Complete Response Rates in Patients with Previously Untreated Follicular Lymphoma: Results of a Phase II Study
39. Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Gastric MALT Lymphoma
40. Double hit lymphoma: the MD Anderson Cancer Center clinical experience
41. Use of Chemotherapy Within the Last 14 Days of Life in Patients Treated at a Comprehensive Cancer Center
42. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma
43. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma
44. A Multidisciplinary Team Approach to Improving Psychosocial Care in Patients With Cancer
45. Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo®) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas
46. Colaboradores
47. Persistent Overall Response on Early PET/CT Scans during Salvage Therapy for Relapsed or Refractory DLBCL Predicts for Disease Specific Survival
48. Treatment and Outcome of Patients with Follicular Lymphoma Relapsed or Progressed after Frontline Lenalidomide and Rituximab
49. The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL)
50. Clinical Efficacy of Polatuzumab Vedotin in Patients with Relapsed/Refractory Large B-Cell Lymphoma after Standard of Care Axicabtagene Ciloleucel
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.